Genmab, Global Agreement for HuMax-CD20 Receives Antitrust Clearance

February 05, 2007 16:21 ET | Source: Genmab A/S Genmab A/S

The worldwide agreement to co-develop and commercialize HuMax-CD20 entered into between Genmab and GSK has received antitrust clearance.

Attachments

102668.pdf...

Recommended Reading

August 25, 2026 09:00 ET | Source: Genmab A/S

Genmab to Participate in Upcoming Investor Conferences

Media ReleaseCOPENHAGEN, Denmark; August 25, 2026Genmab A/S (Nasdaq: GMAB) announced today that members of its Executive Committee will participate in fireside chats at the following investor...
Read More
August 11, 2026 13:53 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The...
Read More